NASDAQ:CDNA - CareDx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$36.92 -2.29 (-5.84 %)
(As of 03/24/2019 06:45 AM ET)
Previous Close$36.92
Today's Range$36.76 - $39.38
52-Week Range$6.33 - $39.38
Volume732,034 shs
Average Volume1.01 million shs
Market Capitalization$1.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.21
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence-specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction methodology; and TruSight HLA, a high resolution solution that uses next generation sequencing methodology. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$76.57 million
Book Value$2.47 per share

Profitability

Net Income$-46,760,000.00

Miscellaneous

Employees227
Market Cap$1.54 billion
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

CareDx (NASDAQ:CDNA) Frequently Asked Questions

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How were CareDx's earnings last quarter?

CareDx Inc (NASDAQ:CDNA) issued its earnings results on Wednesday, March, 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.02. The business had revenue of $23.51 million for the quarter, compared to analysts' expectations of $23.34 million. CareDx had a negative net margin of 61.06% and a negative return on equity of 63.64%. View CareDx's Earnings History.

When is CareDx's next earnings date?

CareDx is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for CareDx.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2019 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $105-107 million, compared to the consensus revenue estimate of $103.6 million.

What price target have analysts set for CDNA?

5 Wall Street analysts have issued 1 year price targets for CareDx's shares. Their forecasts range from $30.00 to $46.00. On average, they anticipate CareDx's share price to reach $38.60 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for CareDx.

What is the consensus analysts' recommendation for CareDx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

What are Wall Street analysts saying about CareDx stock?

Here are some recent quotes from research analysts about CareDx stock:
  • 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (3/7/2019)
  • 2. HC Wainwright analysts commented, "As we roll forward the DCF analysis, our estimated market value of the firm has increased slightly to $1,127M from $1,123M, Our price target is derived from the market value of the firm, which includes a discounted cash flow analysis based asset value for pre- and post-transplant tests, using a 15% discount rate and 2%." (2/4/2019)

Has CareDx been receiving favorable news coverage?

Media stories about CDNA stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CareDx earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the next several days.

Who are some of CareDx's key competitors?

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Twilio (TWLO), Square (SQ), Advanced Micro Devices (AMD), Tandem Diabetes Care (TNDM), Micron Technology (MU), Alibaba Group (BABA), NVIDIA (NVDA), Cronos Group (CRON), Nutanix (NTNX) and Sarepta Therapeutics (SRPT).

Who are CareDx's key executives?

CareDx's management team includes the folowing people:
  • Dr. Peter Maag, CEO & Director (Age 52)
  • Mr. Michael Bell, Chief Financial Officer (Age 50)
  • Dr. James P. Yee, Chief Medical Officer (Age 70)
  • Dr. Reginald Seeto, Pres & Chief Bus. Officer (Age 47)
  • Mr. Anders Karlsson, Chief International Bus. Officer (Age 55)

Who are CareDx's major shareholders?

CareDx's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.41%), Lord Abbett & CO. LLC (3.84%), Gagnon Securities LLC (3.41%), Peregrine Capital Management LLC (1.45%), Two Sigma Advisers LP (1.41%) and Bellevue Group AG (1.38%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Institutional Ownership Trends for CareDx.

Which major investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Gagnon Advisors LLC, Gagnon Securities LLC, Two Sigma Investments LP, Perceptive Advisors LLC, Royce & Associates LP, Chicago Equity Partners LLC, RTW Investments LP and Peregrine Capital Management LLC. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Insider Buying and Selling for CareDx.

Which major investors are buying CareDx stock?

CDNA stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, MUFG Securities EMEA plc, MUFG Securities EMEA plc, Kornitzer Capital Management Inc. KS, Bellevue Group AG, BlackRock Inc., Crawford Lake Capital Management LLC and Picton Mahoney Asset Management. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $36.92.

How big of a company is CareDx?

CareDx has a market capitalization of $1.54 billion and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.

What is CareDx's official website?

The official website for CareDx is http://www.caredxinc.com.

How can I contact CareDx?

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]


MarketBeat Community Rating for CareDx (NASDAQ CDNA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  490
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel